Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
To evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
Epistemonikos ID: 83d96b8ef6e2bcc5e130f029a7be98557a747a3f
First added on: Mar 27, 2025